733: How a pharmacist can ensure the best possible outcomes for status epilepticus
732: Is the vancomycin – piperacillin-tazobactam AKI interaction just pseudotoxicity?
731: Company sponsored indrect comparison concludes the company’s product is better for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage
730: Does the bispectral index correlate well to commonly used sedation scales?
729: What Works Best for Toxin-Related Status Epilepticus?
728: Acetazolamide as a respiratory stimulant
727: Dealing with and preventing negative interactions with other professionals
726: Why can’t Paxlovid be crushed?
725: Clinically relevant pharmacokinetic knowledge on antibiotic dosing (part 3 of 3)
724: Clinically relevant pharmacokinetic knowledge on antibiotic dosing (part 2 of 3)
723: Clinically relevant pharmacokinetic knowledge on antibiotic dosing (part 1)
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 82
- Next Page »